Gastrointestinal neuroendocrine tumors
Conditions
Interventions
XELOX (oxaliplatin combined with capecitabine) :None
Sponsors
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed as gastrointestinal neuroendocrine carcinoma by histopathological examination; 2. Patients who have undergone radical tumor resection regardless of the stage; 3. Gender not limited, aged 18-75 years old; 4. Eastern Cooperative Oncology Group (ECOG) performance status score: = 3 months; 6. Agree to undergo testing, treatment and follow-up in accordance with this research protocol, agree to provide the clinical pathology and follow-up data required by this study, and agree to use the data from this study for subsequent research; 7. Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Participants were excluded if they had any other malignant tumors within the previous 5 years. 2. Participants were excluded if they had received any anti-tumor treatment within the previous 6 months. 3. According to the investigator's judgment, there were serious accompanying diseases (such as poorly controlled hypertension, severe diabetes, thyroid disorders, and mental illnesses, etc.) or any other conditions that could seriously endanger the safety of the patients or affect their ability to complete this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-Free Survival (DFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Side effects; | — |
Countries
China
Contacts
Public ContactYou tingting
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Outcome results
None listed